Archaea Bioprocess Platform for microbiome innovation


Today’s microbiome research is revealing the critical role of archaea in maintaining stable microbial ecosystems in the human gut. Among these organisms, Methanobrevibacter smithii is the most abundant archaeon in the human gut microbiome and plays a central role in microbial metabolism and ecosystem balance.

TwentyGreen SA develops scalable anaerobic bioprocess technologies enabling scaleable cultivation of beneficial human gut archaea. Our platform focuses on the controlled fermentation and production of Methanobrevibacter smithii biomass to unlock new applications in microbiome therapeutics, diagnostics and nutritional science.

Our platform is designed to unlock new applications across microbiome science and biotechnology, including:

1. Development of archaeal therapeutics for microbiome-related diseases
2. Support for microbiome diagnostics and precision nutrition through our sister company ARKAIYA SA at EPFL Innovation Park
3. Industrial bioprocess development for anaerobic gut microorganisms
4. Provision of archaeal strains and biomass for advanced microbiome research

 

By developing scalable archaeal bioprocess technologies, TwentyGreen aims to establish a new platform for microbiome innovation bridging research, diagnostics and therapeutic development.

TwentyGreen has developed proprietary fermentation and bioprocess expertise enabling the scalable cultivation of Methanobrevibacter smithii. This capability opens new opportunities for studying and applying archaeal biology across medicine, microbiome science and biotechnology.

The company collaborates with an international network of academic and clinical partners including EPFL and the University of Bern. Together these collaborations aim to advance understanding of archaeal biology and translate these discoveries into practical health applications.